Compare LOCO & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | HELP |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.3M | 281.4M |
| IPO Year | 2014 | N/A |
| Metric | LOCO | HELP |
|---|---|---|
| Price | $11.28 | $5.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $14.50 | ★ $95.00 |
| AVG Volume (30 Days) | 130.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.22 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $401,701,000.00 | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | $16.16 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $8.29 | $5.25 |
| 52 Week High | $11.74 | $8.55 |
| Indicator | LOCO | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 41.02 |
| Support Level | $10.16 | N/A |
| Resistance Level | $11.44 | $7.28 |
| Average True Range (ATR) | 0.27 | 0.66 |
| MACD | 0.03 | -0.19 |
| Stochastic Oscillator | 82.69 | 17.65 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.